40 results on '"Perona M"'
Search Results
2. A new framework for supply chain management : Conceptual model and empirical test
- Author
-
Cigolini, R., Cozzi, M., and Perona, M.
- Published
- 2004
- Full Text
- View/download PDF
3. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)
- Author
-
Nyssen O. P., Vaira D., Tepes B., Kupcinskas L., Bordin D., Perez-Aisa A., Gasbarrini A., Castro-Fernandez M., Bujanda L., Garre A., Lucendo A. J., Vologzhanina L., Jurecic N. B., Rodrigo-Saez L., Huguet J. M., Voynovan I., Perez-Lasala J., Romero P. M., Vujasinovic M., Abdulkhakov R., Barrio J., Fernandez-Salazar L., Megraud F., O'Morain C., Gisbert J. P., Ilchishina T., Arino I., Zaytsev O., Perona M., Sarsenbaeva A. S., Ortuno J., Alekseenko S., Dominguez-Cajal M., Rodriguez B. J. G., Notari P. A., Pellicano R., Consorci I. M., Nardone G., Bote J. M. B. -A., Nunez O., Gomez-Camarero J., Guadix J. H., Fiorini G., Jonaitis L., Galan H. A., Ferrer L., Molina-Infante J., Kikec Z., Alcaide N., Lanas A., Sant'Orsola V. C., Medina-Chulia E., Canelles P., Santos-Fernandez J., Velayos B., Di Maira T., Lafuente M. R., Moreno M. J., Dekhnich N. N., Varela P., de la Coba C., Osipenko M. F., Lopez R. R. -Z., Huerta-Madrigal A., Livzan M. A., Pozzati L. S., Iyo E., Amelchugova O. S., Vasyutin A. V., Tsukanov V. V., Barenys M., Burkov S. G., Gravina A. G., Romano M., Bakulina N. V., Fernandez-Bermejo M., Alcedo J., Franceschi F., Campillo A., Seruga M., Villarroya R. P., Mego M., Dore M. P., Tito L., Gmez B., Jimenez J. L. D., Bermejo F., Algaba A., Belousova L. N., Plotnikova E. Y., Calvet X., Figuerola A., Tarasova L., Grigorieva L., Amorena E., Estremera F., Sanchez-Pobre P., Millastre J., Tomas A., Baryshnikova N., Kucheryavyy Y. A., Kononova A., Bakulin I., Cerezo F. J. M., Venciene R., Zhestkova T. V., Rocco A., Gonzalez Santiago J. M., Nyssen, O. P., Vaira, D., Tepes, B., Kupcinskas, L., Bordin, D., Perez-Aisa, A., Gasbarrini, A., Castro-Fernandez, M., Bujanda, L., Garre, A., Lucendo, A. J., Vologzhanina, L., Jurecic, N. B., Rodrigo-Saez, L., Huguet, J. M., Voynovan, I., Perez-Lasala, J., Romero, P. M., Vujasinovic, M., Abdulkhakov, R., Barrio, J., Fernandez-Salazar, L., Megraud, F., O'Morain, C., Gisbert, J. P., Ilchishina, T., Arino, I., Zaytsev, O., Perona, M., Sarsenbaeva, A. S., Ortuno, J., Alekseenko, S., Dominguez-Cajal, M., Rodriguez, B. J. G., Notari, P. A., Pellicano, R., Consorci, I. M., Nardone, G., Bote, J. M. B. -A., Nunez, O., Gomez-Camarero, J., Guadix, J. H., Fiorini, G., Jonaitis, L., Galan, H. A., Ferrer, L., Molina-Infante, J., Kikec, Z., Alcaide, N., Lanas, A., Sant'Orsola, V. C., Medina-Chulia, E., Canelles, P., Santos-Fernandez, J., Velayos, B., Di Maira, T., Lafuente, M. R., Moreno, M. J., Dekhnich, N. N., Varela, P., de la Coba, C., Osipenko, M. F., Lopez, R. R. -Z., Huerta-Madrigal, A., Livzan, M. A., Pozzati, L. S., Iyo, E., Amelchugova, O. S., Vasyutin, A. V., Tsukanov, V. V., Barenys, M., Burkov, S. G., Gravina, A. G., Romano, M., Bakulina, N. V., Fernandez-Bermejo, M., Alcedo, J., Franceschi, F., Campillo, A., Seruga, M., Villarroya, R. P., Mego, M., Dore, M. P., Tito, L., Gmez, B., Jimenez, J. L. D., Bermejo, F., Algaba, A., Belousova, L. N., Plotnikova, E. Y., Calvet, X., Figuerola, A., Tarasova, L., Grigorieva, L., Amorena, E., Estremera, F., Sanchez-Pobre, P., Millastre, J., Tomas, A., Baryshnikova, N., Kucheryavyy, Y. A., Kononova, A., Bakulin, I., Cerezo, F. J. M., Venciene, R., Zhestkova, T. V., Rocco, A., Gonzalez Santiago, J. M., Lucendo, A., and the Hp-EuReg, Investigator
- Subjects
Registrie ,medicine.medical_specialty ,Proton Pump Inhibitor ,medicine.drug_class ,Settore MED/12 - GASTROENTEROLOGIA ,Antibiotics ,MEDLINE ,Helicobacter Infections ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Drug Therapy ,Clarithromycin ,Internal medicine ,Metronidazole ,Anti-Bacterial Agent ,bismuth ,medicine ,non-bismuth ,Humans ,Prospective Studies ,Registries ,Disease management (health) ,levofloxacin ,biology ,Helicobacter pylori ,business.industry ,mistake ,Gastroenterology ,Amoxicillin ,Proton Pump Inhibitors ,biology.organism_classification ,error ,Anti-Bacterial Agents ,Penicillin ,Prospective Studie ,030220 oncology & carcinogenesis ,Combination ,030211 gastroenterology & hepatology ,Drug Therapy, Combination ,business ,Helicobacter Infection ,H. pylori ,medicine.drug ,Human - Abstract
BACKGROUND: Managing Helicobacter pylori infection requires constant decision making, and each decision is open to possible errors. AIM: The aim was to evaluate common mistakes in the eradication of H. pylori, based on the "European Registry on Helicobacter pylori management". METHODS: European Registry on Helicobacter pylori management is an international multicentre prospective noninterventional registry evaluating the decisions and outcomes of H. pylori management by European gastroenterologists in routine clinical practice. RESULTS: Countries recruiting more than 1000 patients were included (26,340 patients). The most common mistakes (percentages) were: (1) To use the standard triple therapy where it is ineffective (46%). (2) To prescribe eradication therapy for only 7 to 10 days (69%). (3) To use a low dose of proton pump inhibitors (48%). (4) In patients allergic to penicillin, to prescribe always a triple therapy with clarithromycin and metronidazole (38%). (5) To repeat certain antibiotics after eradication failure (>15%). (6) Failing to consider the importance of compliance with treatment (2%). (7) Not to check the eradication success (6%). Time-trend analyses showed progressive greater compliance with current clinical guidelines. CONCLUSION: The management of H. pylori infection by some European gastroenterologists is heterogeneous, frequently suboptimal and discrepant with current recommendations. Clinical practice is constantly adapting to updated recommendations, although this shift is delayed and slow.
- Published
- 2020
4. Static compliance and driving pressure are associated with ICU mortality in intubated COVID-19 ARDS
- Author
-
Boscolo, A., Sella, N., Lorenzoni, G., Pasin, L., Pretto, C., Tocco, M., Tamburini, E., De Cassai, A., Rosi, P., Polati, E., Donadello, K., Gottin, L., De Rosa, S., Baratto, F., Toffoletto, F., Ranieri, V. M., Gregori, D., Navalesi, P., Valeri, I., Andreatta, G., Gandolfi, L., Gadaldi, A., Brumana, N., Forin, E., Correale, C., Pesenti, E., Fregolent, D., Pirelli, P. F., Marchesin, D., Perona, M., Franchetti, N., Della Paolera, M., Simoni, C., Falcioni, T., Tresin, A., Schiavolin, C., Schiavi, A., Vathi, S., Sartori, D., Sorgato, A., Pistollato, E., Serra, E., Pittarello, D., Tiberio, I., Bond, O., Michieletto, E., Muraro, L., Peralta, A., Persona, P., Petranzan, E., Zarantonello, F., Graziano, A., Piasentini, E., Bernardi, L., Pianon, R., Badii, F., Bosco, E., Agostini, M., Farnia, A., Peta, M., Calo, M. A., Meggiolaro, M., Lazzari, F., Martinello, I., Fullin, G., Papaccio, F., Bonato, A., Sgarabotto, C., Montacciani, F., Alessandra, P., Gagliardi, G., Ferraro, G., Ongaro, L., Baiocchi, M., Danzi, V., Zanatta, P., Marchiotto, S., Bassanini, S., Zamperini, M., Daroui, I., Linassi, F., and Pettenuzzo, T.
- Subjects
Male ,ARDS ,Supine position ,COVID-19 ,Driving pressure ,Mechanical ventilation ,Respiratory system compliance ,medicine.medical_treatment ,Pulmonary compliance ,Critical Care and Intensive Care Medicine ,Hypoxemia ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Tidal Volume ,Humans ,Medicine ,Tidal volume ,Aged ,Respiratory Distress Syndrome ,RC86-88.9 ,business.industry ,Respiration ,Research ,Medical emergencies. Critical care. Intensive care. First aid ,030208 emergency & critical care medicine ,Middle Aged ,medicine.disease ,Respiration, Artificial ,Intensive care unit ,Intensive Care Units ,Female ,Intubation ,Italy ,030228 respiratory system ,Anesthesia ,Artificial ,medicine.symptom ,business ,Cohort study - Abstract
Background Pathophysiological features of coronavirus disease 2019-associated acute respiratory distress syndrome (COVID-19 ARDS) were indicated to be somewhat different from those described in nonCOVID-19 ARDS, because of relatively preserved compliance of the respiratory system despite marked hypoxemia. We aim ascertaining whether respiratory system static compliance (Crs), driving pressure (DP), and tidal volume normalized for ideal body weight (VT/kg IBW) at the 1st day of controlled mechanical ventilation are associated with intensive care unit (ICU) mortality in COVID-19 ARDS. Methods Observational multicenter cohort study. All consecutive COVID-19 adult patients admitted to 25 ICUs belonging to the COVID-19 VENETO ICU network (February 28th–April 28th, 2020), who received controlled mechanical ventilation, were screened. Only patients fulfilling ARDS criteria and with complete records of Crs, DP and VT/kg IBW within the 1st day of controlled mechanical ventilation were included. Crs, DP and VT/kg IBW were collected in sedated, paralyzed and supine patients. Results A total of 704 COVID-19 patients were screened and 241 enrolled. Seventy-one patients (29%) died in ICU. The logistic regression analysis showed that: (1) Crs was not linearly associated with ICU mortality (p value for nonlinearity = 0.01), with a greater risk of death for values 2O; (2) the association between DP and ICU mortality was linear (p value for nonlinearity = 0.68), and increasing DP from 10 to 14 cmH2O caused significant higher odds of in-ICU death (OR 1.45, 95% CI 1.06–1.99); (3) VT/kg IBW was not associated with a significant increase of the risk of death (OR 0.92, 95% CI 0.55–1.52). Multivariable analysis confirmed these findings. Conclusions Crs 2O was associated with ICU mortality, while DP was linearly associated with mortality. DP should be kept as low as possible, even in the case of relatively preserved Crs, irrespective of VT/kg IBW, to reduce the risk of death.
- Published
- 2021
5. Outcomes of COVID-19 patients intubated after failure of non-invasive ventilation: a multicenter observational study
- Author
-
Boscolo, A., Pasin, L., Sella, N., Pretto, C., Tocco, M., Tamburini, E., Rosi, P., Polati, E., Donadello, K., Gottin, L., Vianello, A., Landoni, G., Navalesi, P., Valeri, I., Andreatta, G., Gandolfi, L., Gadaldi, A., Brumana, N., Forin, E., Correale, C., Fregolent, D., Pirelli, P. F., Marchesin, D., Perona, M., Franchetti, N., Paolera, M. D., Simoni, C., Falcioni, T., Tresin, A., Schiavolin, C., Schiavi, A., Vathi, S., Sartori, D., Sorgato, A., Pistollato, E., Golino, G. L., Frigo, L., Serra, E., Pittarello, D., Tiberio, I., Bond, O., Michieletto, E., Muraro, L., Peralta, A., Persona, P., Petranzan, E., Zarantonello, F., Graziano, A., De Cassai, A., Bernardi, L., Pianon, R., Badii, F., Bosco, E., Agostini, M., Trevisiol, P., Farnia, A., Peta, M., Altafini, L., Calo, M. A., Meggiolaro, M., Lazzari, F., Martinello, I., Fullin, G., Papaccio, F., Toffoletto, F., Bonato, A., Sgarabotto, C., Baratto, F., Montacciani, F., Parnigotto, A., Gagliardi, G., Gioconda, F., Ongaro, L., Baiocchi, M., Danzi, V., De Rosa, S., Zanatta, P., Sinigaglia, E., da Ros, A., Marchiotto, S., Bassanini, S., Zamperini, M., Daroui, I., Mosaner, W., Lembo, R., Linassi, F., and Pettenuzzo, T.
- Subjects
Male ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Respiratory distress syndrome ,Outcome Assessment ,Science ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Endotracheal intubation ,Article ,law.invention ,law ,Risk Factors ,Outcome Assessment, Health Care ,medicine ,Intubation, Intratracheal ,Humans ,Hospital Mortality ,Aged ,COVID-19 ,Female ,Intensive Care Units ,Logistic Models ,Middle Aged ,Multivariate Analysis ,Noninvasive Ventilation ,Respiratory Insufficiency ,SARS-CoV-2 ,Multidisciplinary ,business.industry ,Intensive care unit ,Icu admission ,Health Care ,Intratracheal ,Multicenter study ,Emergency medicine ,Breathing ,Medicine ,Observational study ,business ,Intubation - Abstract
IntroductionThe efficacy of non-invasive ventilation (NIV) in acute respiratory failure secondary to SARS-CoV-2 infection remains controversial. Current literature mainly examined efficacy, safety and potential predictors of NIV failure provided out of the Intensive Care Unit (ICU). On the contrary, the outcomes of ICU patients, intubated after NIV failure, remain to be explored. The aims of the present study are: 1) investigating in-hospital mortality in coronavirus disease 2019 (COVID-19) ICU patients receiving endotracheal intubation after NIV failure and 2) assessing whether the length of NIV application affects patient survival. MethodsThis observational multicenter study included all consecutive COVID-19 adult patients, admitted into the twenty-five ICUs of the COVID-19 VENETO ICU network (February-April 2020), who underwent endotracheal intubation after NIV failure. ResultsAmong the 704 patients admitted to ICU during the study period, 280 (40%) presented the inclusion criteria and were enrolled. The median age was 69 [60-76] years; 219 patients (78%) were male. In-hospital mortality was 43%. Only the length of NIV application before ICU admission (OR 2.03 (95% CI 1.06 - 4.98), p = 0.03) and age (OR 1.18 (95% CI 1.04 - 1.33), p < 0.01) were identified as independent risk factors of in-hospital mortality; whilst the length of NIV after ICU admission did not affect patient outcome. ConclusionsIn-hospital mortality of ICU patients intubated after NIV failure was 43%. Days on NIV before ICU admission and age were assessed to be potential risk factors of greater in-hospital mortality.
- Published
- 2021
6. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice
- Author
-
Nyssen, O. P., Perez-Aisa, A., Castro-Fernandez, M., Pellicano, R., Huguet, J. M., Rodrigo, L., Ortun, J., O, Gomez-Rodriguez, B. J., Pinto, R. M., Areia, M., Perona, M., Nunez, O., Romano, M., Gravina, A. G., Pozzati, L., Fernandez-Bermejo, M., Venerito, M., Malfertheiner, P., Fernanadez-Salazar, L., Gasbarrini, Antonio, Vaira, D., Puig, I., Megraud, F., O'Morain, C., Gisbert, J. P., Gasbarrini A. (ORCID:0000-0002-7278-4823), Nyssen, O. P., Perez-Aisa, A., Castro-Fernandez, M., Pellicano, R., Huguet, J. M., Rodrigo, L., Ortun, J., O, Gomez-Rodriguez, B. J., Pinto, R. M., Areia, M., Perona, M., Nunez, O., Romano, M., Gravina, A. G., Pozzati, L., Fernandez-Bermejo, M., Venerito, M., Malfertheiner, P., Fernanadez-Salazar, L., Gasbarrini, Antonio, Vaira, D., Puig, I., Megraud, F., O'Morain, C., Gisbert, J. P., and Gasbarrini A. (ORCID:0000-0002-7278-4823)
- Abstract
Background: There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation. Objective: To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy. Methods: Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pylori infection, where patients were registered at the Asociación Española de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line. Results: Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e., three capsules every 6 h for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n = 1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n = 375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n = 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases. Conclusions: Single-capsule bismuth quadruple therapy achieved H. pylori eradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourab
- Published
- 2021
7. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy forHelicobacter pyloriinfection: Spanish data of the EuropeanHelicobacter pyloriRegistry (Hp-EuReg)
- Author
-
Nyssen, OP, Perez-Aisa, A, Rodrigo, L, Castro, M, Romero, PM, Ortu?o, J, Barrio, J, Huguet, JM, Modollel, I, Alcaide, N, Lucendo, A, Calvet, X, Perona, M, Gomez, B, Rodriguez, BJG, Varela, P, Jimenez-Moreno, M, Dominguez-Cajal, M, Pozzati, L, Burgos, D, Bujanda, L, Hinojosa, J, Molina-Infante, J, Di Maira, T, Ferrer, L, Fern?ndez-Salazar, L, Figuerola, A, Tito, L, de la Coba, C, Gomez-Camarero, J, Fernandez, N, Caldas, M, Garre, A, Resina, E, Puig, I, O'Morain, C, Megraud, F, and Gisbert, JP
- Subjects
metronidazole ,doxycycline ,Helicobacter pylori ,bismuth ,polycyclic compounds ,Pylera(R) ,tetracycline - Abstract
Background Different bismuth quadruple therapies containing proton-pump inhibitors, bismuth salts, metronidazole, and a tetracycline have been recommended as third-lineHelicobacter pylorieradication treatment after failure with clarithromycin and levofloxacin. Aim To evaluate the efficacy and safety of third-line treatments with bismuth, metronidazole, and either tetracycline or doxycycline. Methods Sub-study with Spanish data of the "European Registry onH pyloriManagement" (Hp-EuReg), international multicenter prospective non-interventional Registry of the routine clinical practice of gastroenterologists. After previous failure with clarithromycin- and levofloxacin-containing therapies, patients receiving a third-line regimen with 10/14-day bismuth salts, metronidazole, and either tetracycline (BQT-Tet) or doxycycline (BQT-Dox), or single capsule (BQT-three-in-one) were included. Data were registered at AEG-REDCap database. Univariate and multivariate analyses were performed. Results Four-hundred and fifty-four patients have been treated so far: 85 with BQT-Tet, 94 with BQT-Dox, and 275 with BQT-three-in-one. Average age was 53 years, 68% were women. Overall modified intention-to-treat and per-protocol eradication rates were 81% (BQT-Dox: 65%, BQT-Tet: 76%, BQT-three-in-one: 88%) and 82% (BQT-Dox: 66%, BQT-Tet: 77%, BQT-three-in-one: 88%), respectively. By logistic regression, higher eradication rates were associated with compliance (OR = 2.96; 95% CI = 1.01-8.84) and no prior metronidazole use (OR = 1.96; 95% CI = 1.15-3.33); BQT-three-in-one was superior to BQT-Dox (OR = 4.46; 95% CI = 2.51-8.27), and BQT-Tet was marginally superior to BQT-Dox (OR = 1.67; 95% CI = 0.85-3.29). Conclusion Third-lineH pylorieradication with bismuth quadruple treatment (after failure with clarithromycin and levofloxacin) offers acceptable efficacy and safety. Highest efficacy was found in compliant patients and those taking 10-day BQT-three-in-one or 14-day BQT-Tet. Doxycycline seems to be less effective and therefore should not be recommended.
- Published
- 2020
8. European Registry on Helicobacter pylori Management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice
- Author
-
Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuño J, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gerarda Gravina A, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, and Gisbert JP
- Subjects
inorganic chemicals ,Helicobacter pylori ,Pylera ,Helicobacter pylori, Pylera, bismuth, eradication, quadruple ,quadruple ,equipment and supplies ,bacterial infections and mycoses ,digestive system ,digestive system diseases ,bismuth ,eradication - Abstract
BACKGROUND: There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation. OBJECTIVE: To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy. METHODS: Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pylori infection, where patients were registered at the Asociacion Espanola de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line. RESULTS: Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e. three capsules every 6 hours for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n=1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n=375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n=236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases. CONCLUSIONS: Single-capsule bismuth quadruple therapy achieved H. pylori eradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourable safety profile.
- Published
- 2020
9. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)
- Author
-
Nyssen, O. P., Perez-Aisa, A., Tepes, B., Rodrigo-Saez, L., Romero, P. M., Lucendo, A., Castro-Fernandez, M., Phull, P., Barrio, J., Bujanda, L., Ortuno, J., Areia, M., Brglez Jurecic, N., Huguet, J. M., Alcaide, N., Voynovan, I., Maria Botargues Bote, J., Modolell, I., Perez Lasala, J., Arino, I., Jonaitis, L., Dominguez-Cajal, M., Buzas, G., Lerang, F., Perona, M., Bordin, D., Axon, T., Gasbarrini, Antonio, Marcos Pinto, R., Niv, Y., Kupcinskas, L., Tonkic, A., Leja, M., Rokkas, T., Boyanova, L., Shvets, O., Venerito, M., Bytzer, P., Goldis, A., Simsek, I., Lamy, V., Przytulski, K., Kunovsky, L., Capelle, L., Milosavljevic, T., Caldas, M., Garre, A., Megraud, F., O'Morain, C., Gisbert, J. P., Hinojosa, J., Fernandez, N., Molina Infante, J., Alonso Galan, H., Di Maira, T., Alves, S. I., Saraiva, S., Elvas, L., Brito, D., Teresa Cadime, A., Lampic, P., Gruncic, A., Leban, V., Ferrer, L., Fernandez Salazar, L., Lanas, A., Kristensen, V., Brackmann, S., Delchier, J. C., Anton, C., Gomez Rodriguez, B. J., Pellicano, R., Boltin, D., and Gastroenterology & Hepatology
- Subjects
medicine.medical_specialty ,Allergy ,Settore MED/12 - GASTROENTEROLOGIA ,allergic ,Penicillins ,Gastroenterology ,Helicobacter Infections ,Drug Hypersensitivity ,03 medical and health sciences ,0302 clinical medicine ,Levofloxacin ,Metronidazole ,Clarithromycin ,Internal medicine ,bismuth ,medicine ,Humans ,Prospective Studies ,Registries ,Adverse effect ,levofloxacin ,biology ,Helicobacter pylori ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,allergy ,clarithromycin ,penicillin ,Proton Pump Inhibitors ,General Medicine ,Tetracycline ,biology.organism_classification ,medicine.disease ,Anti-Bacterial Agents ,3. Good health ,Penicillin ,Regimen ,Infectious Diseases ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Background Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended. Aim To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg). Methods A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infection. An e-CRF was created on AEG-REDCap. Patients with penicillin allergy were analyzed until June 2019. Results One-thousand eighty-four patients allergic to penicillin were analyzed. The most frequently prescribed first-line treatments were as follows: PPI + C + M (n = 285) and PPI + B + T + M (classic or Pylera(R); n = 250). In first line, the efficacy of PPI + C + M was 69%, while PPI + B + T + M reached 91% (P < .001). In second line, after the failure of PPI + C + M, two rescue options showed similar efficacy: PPI + B + T + M (78%) and PPI + C + levofloxacin (L) (71%) (P > .05). In third line, after the failure of PPI + C + M and PPI + C + L, PPI + B + T + M was successful in 75% of cases. Conclusion In patients allergic to penicillin, a triple combination with PPI + C + M should not be generally recommended as a first-line treatment, while a quadruple regimen with PPI + B + T + M seems to be a better option. As a rescue treatment, this quadruple regimen (if not previously prescribed) or a triple regimen with PPI + C + L could be used but achieved suboptimal (
- Published
- 2020
10. Configuring the after-sales service supply chain: A multiple case study
- Author
-
Saccani, N., Johansson, P., and Perona, M.
- Published
- 2007
- Full Text
- View/download PDF
11. Work-force management in automated assembly systems
- Author
-
Croci, F., Perona, M., and Pozzetti, A.
- Subjects
Assembly-line methods -- Management ,Factories -- Human resource management ,Scheduling (Management) -- Tests, problems and exercises ,Business ,Business, international ,Engineering and manufacturing industries - Abstract
While issues like off-line short-term scheduling, sequencing, real-time control and rescheduling of automated manufacturing or assembly systems are well established and widely discussed in literature, human resources have seldom been considered a critical management parameter in the addressed industrial contexts, since they are characterized by a high level of automation. The objective of this study is the assessment of the influence of work force and related management policies on the operating performances of an automated assembly system. Although workers' main tasks, in these systems, are characterized by short duration and tend to be spaced by long intervals, during which automated machines operate autonomously, it is postulated that the way the human interventions on the system is organized may have a profound impact on its performances. For this purpose, a simulation model of a real automated PCB assembly system has been used to test the comparative effectiveness and efficiency of different work-force management rules. More in detail, we compared several work-force management contexts differing in the number of workers in the crew, the way tasks are assigned to operators and the way operators are assigned to machines in the shop. The obtained results allowed us to disclose useful directions on work-force management in automated systems, highlighting how job enlargement issues, typical of lean production philosophy, have great relevance in determining the best work-force management policies.
- Published
- 2000
12. Helicobacter Pylori Infection Does Not Protect Against Eosinophilic Esophagitis: Results From a Large Multicenter Case-Control Study
- Author
-
Molina-Infante, J, Gutierrez-Junquera, C, Savarino, E, Penagini, R, Modolell, I, Bartolo, O, Prieto-Garcia, A, Mauro, A, Alcedo, J, Perello, A, Guarner-Argente, C, Alcaide, N, Vegas, AM, Barros-Garcia, P, Murzi-Pulgar, M, Perona, M, Gisbert, JP, Lucendo, AJ, and Upper GI Tract Study Grp Spanish
- Abstract
OBJECTIVES: Rising trends in eosinophilic esophagitis (EoE) have been repeatedly linked to declining Helicobacter pylori (H. pylori) infection, mostly in retrospective studies. We aimed to prospectively evaluate this inverse association. METHODS: Prospective case-control study conducted in 23 centers. Children and adults naive to eradication therapy for H. pylori were included. Cases were EoE patients, whereas controls were defined by esophageal symptoms and
- Published
- 2018
13. Le prove ABCA 14-16
- Author
-
BACCAGLINI-FRANK, ANNA ETHELWYN, Bettini, P, Brazzolotto, M, Caviola, S, Perona, M, and Poli, F.
- Published
- 2014
14. Il Potenziamento in Matematica di Studenti del Biennio Superiore: il successo di particolari strategie cognitive
- Author
-
ANNA ETHELWYN BACCAGLINI FRANK, Lucatello, B., Micheletto, L., Perona, M., and Tubertini, M.
- Published
- 2013
15. Un Percorso di Potenziamento in Matematica per Studenti del Biennio Superiore
- Author
-
ANNA ETHELWYN BACCAGLINI FRANK, Lucangeli, D., Lucatello, B., Micheletto, L., Perona, M., and Tubertini, M.
- Published
- 2013
16. Potenziare l'apprendimento della matematica nel biennio delle superiori attraverso adeguate strategie cognitive
- Author
-
ANNA ETHELWYN BACCAGLINI FRANK, Lucatello, B., Micheletto, L., and Perona, M.
- Published
- 2013
17. Correlations between first and second trimester markers for Down's syndrome screening
- Author
-
Campogrande, M, Viora, E, Errante, G, Bastonero, S, Sciarrone, A, Pirrone, P Grassi, Perona, M, Mancini, G, Dall'Amico, D, Pavanello, E, and Guaraldo, V
- Subjects
Birth defects -- Diagnosis ,Down syndrome -- Diagnosis ,Prenatal diagnosis ,Health ,Social sciences - Abstract
Second trimester screening for Down's syndrome has been used for many years. [1 2] The triple test, based on alphafetoprotein (AFP), unconjugated estriol ([uE.sub.3]), and human chorionic gonadotropin (hCG), as [...]
- Published
- 2001
18. Dietary restriction mitigates cocaine-induced alterations of olfactory bulb cellular plasticity and gene expression, and behavior
- Author
-
Xu, X., Mughal, M., Scott Hall, F., Perona, M., Pistell, P., Lathia, J., Chigurupati, S., Becker, K., Ladenheim, B., Niklason, L., Uhl, G., Cadet, J., and Mattson, M.
- Abstract
Because the olfactory system plays a major role in food consumption, and because 'food addiction' and associated morbidities have reached epidemic proportions, we tested the hypothesis that dietary energy restriction can modify adverse effects of cocaine on behavior and olfactory cellular and molecular plasticity. Mice maintained on an alternate day fasting (ADF) diet exhibited increased baseline locomotion and increased cocaine-sensitized locomotion during cocaine conditioning, despite no change in cocaine conditioned place preference, compared with mice fed ad libitum. Levels of dopamine and its metabolites in the olfactory bulb (OB) were suppressed in mice on the ADF diet compared with mice on the control diet, independent of acute or chronic cocaine treatment. The expression of several enzymes involved in dopamine metabolism including tyrosine hydroxylase, monoamine oxidases A and B, and catechol-O-methyltransferase were significantly reduced in OBs of mice on the ADF diet. Both acute and chronic administration of cocaine suppressed the production of new OB cells, and this effect of cocaine was attenuated in mice on the ADF diet. Cocaine administration to mice on the control diet resulted in up-regulation of OB genes involved in mitochondrial energy metabolism, synaptic plasticity, cellular stress responses, and calcium- and cAMP-mediated signaling, whereas multiple olfactory receptor genes were down-regulated by cocaine treatment. ADF abolished many of the effects of cocaine on OB gene expression. Our findings reveal that dietary energy intake modifies the neural substrates underlying some of the behavioral and physiological responses to repeated cocaine treatment, and also suggest novel roles for the olfactory system in addiction. The data further suggest that modification of dietary energy intake could provide a novel potential approach to addiction treatments.
- Published
- 2010
19. The after-sales service, aligning supply chain configuration with strategy : evidence from the household appliance industry”
- Author
-
Saccani, Nicola, Johansson, Pontus, Perona, M., Postoni, A., Saccani, Nicola, Johansson, Pontus, Perona, M., and Postoni, A.
- Published
- 2005
20. A new dynamic look-ahead scheduling procedure for batching machines
- Author
-
Cigolini, R., primary, Perona, M., additional, Portioli, A., additional, and Zambelli, T., additional
- Published
- 2002
- Full Text
- View/download PDF
21. Bilateral lumbosacral plexopathy after mesenteric thrombosis.
- Author
-
García-Manzanares, M D, Forner-Cordero, I, Lavara-Perona, M C, Sánchez-Ponce, G, and Gisbert-Vicens, J
- Subjects
MESENTERY ,THROMBOSIS ,ELECTROMYOGRAPHY ,NEURAL conduction ,PERIPHERAL nervous system - Abstract
OBJECTIVE:: A case of lumbosacral plexopathy (LSP) following operation for mesenteric thrombosis. DESIGN:: Case report of a 64-year-old man who developed weakness and numbness of the distal legs after an operation for mesenteric thrombosis. SETTING:: Department of Physical Medicine and Rehabilitation, University Hospital La Fe, Valencia, Spain. SUBJECT:: Single patient case report. MAIN OUTCOME MEASURE:: Clinical and electromyography follow-up of the patient between October 1996 and August 1997. RESULTS:: Physical examination revealed marked lower extremity weakness, hypotonia, hyporreflexia and normal bowel and bladder function. Electromyography demonstrated marked denervation of all major muscle groups, and sensory nerve conduction showed absence of responses in all peripheral nerves, in both legs. CONCLUSION:: To our knowledge, bilateral LSP following an intervention of mesenteric thrombosis, has never been reported in the literature. Diagnosis of LSP might be based on electromyography and nerve conduction studies that demonstrate electrodiagnostic criteria for LSP, including denervation in muscles innervated by at least two lumbosacral segmental levels and involving at least two different peripheral nerves, without paraspinal involvement. [ABSTRACT FROM AUTHOR]
- Published
- 1999
22. Bespoke supply chains: Transforming luxury fashion supply chains
- Author
-
Perona, M., Zanoni, S., Brun, A., Sianesi, A., Karaosman, H., Perona, M., Zanoni, S., Brun, A., Sianesi, A., and Karaosman, H.
- Abstract
Optimal and efficient supply chain (SC) is a function of contingent and decision variables. Among contingencies are environmental and resource variables that must be understood to define operational strategies. The luxury fashion industry is a peculiar sector where SC design must take into account industry specific factors. Undeniably, the industry goes through substantial changes that directly affect operational effectiveness and efficiencies of SCs. Yet, it is not well defined how unexpected market dynamics could be translated into operational strategies. First objective of this research is therefore to define the most critical success factors for the luxury fashion industry. Not withstanding existing studies on the critical factors, it is not clear how luxury fashion SC strategies must be configured in accordance to rapidly changing industrial dynamics and market factors. In order to outline very specific components and to explore how luxury SC strategies must be orchestrated, this study conducts in depth interviews with experts, belonging to companies operating in the luxury fashion industry. Given that there is relatively little research on how to build robust methodological approaches by taking into account context variables, this paper identifies the most profound and critical success variables to stay competitive in the luxury fashion industry, and highlights what could enable luxury companies to adjust their SCs in highly volative and unexpected situations in accordance with the most critical yet contextual variable.
23. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice
- Author
-
Nyssen, Olga P, Perez-Aisa, Angeles, Castro-Fernandez, Manuel, Pellicano, Rinaldo, Huguet, Jose M, Rodrigo, Luis, Ortuñ, Juan, O, Gomez-Rodriguez, Blas J, Pinto, Ricardo M, Areia, Miguel, Perona, Monica, Nuñez, Oscar, Romano, Marco, Gravina, Antonietta G, Pozzati, Liliana, Fernandez-Bermejo, Miguel, Venerito, Marino, Malfertheiner, Peter, Fernanadez-Salazar, Luis, Gasbarrini, Antonio, Vaira, Dino, Puig, Ignasi, Megraud, Francis, O'Morain, Colm, Gisbert, Javier P, Hp-EuReg investigators, UAM. Departamento de Medicina, Nyssen O.P., Perez-Aisa A., Castro-Fernandez M., Pellicano R., Huguet J.M., Rodrigo L., Ortun J., Gomez-Rodriguez B.J., Pinto R.M., Areia M., Perona M., Nunez O., Romano M., Gravina A.G., Pozzati L., Fernandez-Bermejo M., Venerito M., Malfertheiner P., Fernanadez-Salazar L., Gasbarrini A., Vaira D., Puig I., Megraud F., O'Morain C., Gisbert J.P., Nyssen, Op, Perez-Aisa, A, Castro-Fernandez, M, Pellicano, R, Huguet, Jm, Rodrigo, L, Ortuño, J, Gomez-Rodriguez, Bj, Pinto, Rm, Areia, M, Perona, M, Nuñez, O, Romano, M, Gerarda Gravina, A, Pozzati, L, Fernandez-Bermejo, M, Venerito, M, Malfertheiner, P, Fernanadez-Salazar, L, Gasbarrini, A, Vaira, D, Puig, I, Megraud, F, O'Morain, C, and Gisbert, Jp
- Subjects
Registrie ,Male ,Helicobacter pylori infection ,Proton Pump Inhibitor ,Intention to Treat Analysi ,Gastrointestinal Diseases ,Drug Resistance ,Gastroenterology ,Bismuth ,0302 clinical medicine ,Drug Combination ,eradication ,Registries ,Capsule ,biology ,Bacterial ,Middle Aged ,Anti-Bacterial Agents ,Intention to Treat Analysis ,Clinical Practice ,Europe ,Drug Combinations ,Oncology ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Original Article ,Human ,medicine.drug ,inorganic chemicals ,Adult ,medicine.medical_specialty ,Adolescent ,Medicina ,medicine.drug_class ,Tetracycline ,Gastrointestinal Disease ,Settore MED/12 - GASTROENTEROLOGIA ,quadruple ,Proton-pump inhibitor ,chemistry.chemical_element ,Capsules ,digestive system ,Helicobacter Infections ,Medication Adherence ,Neurogastroenterology ,03 medical and health sciences ,Young Adult ,Internal medicine ,Metronidazole ,Anti-Bacterial Agent ,Drug Resistance, Bacterial ,bismuth ,medicine ,Humans ,Helicobacter pylori ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Proton Pump Inhibitors ,equipment and supplies ,bacterial infections and mycoses ,biology.organism_classification ,Pylera ,digestive system diseases ,chemistry ,business ,Helicobacter Infection - Abstract
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM, Background: There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation. Objective: To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy. Methods: Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pylori infection, where patients were registered at the Asociación Española de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line. Results: Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e., three capsules every 6 h for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n = 1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n = 375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n = 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases. Conclusions: Single-capsule bismuth quadruple therapy achieved H. pylori eradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourable safety profile, The author(s) would like to thank the Spanish Association of Gastroenterology (AEG) for providing the electronic case report form service free of charge. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was promoted and funded by the European Helicobacterand Microbiota Study Group, and received support from the Spanish Association of Gastroenterology (AEG) and the Centro de Investigación Biomedica en Red de Enfermedades Hepaticas y Digestivas
- Published
- 2020
24. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments
- Author
-
Monica Perona, Agnese Miranda, Inés Ariño, Judith Gomez-Camarero, Marco Romano, Luis Ferrer-Barceló, Jesús Barrio, Judith Millastre, Blas J. Gomez, Fernando Bermejo, Ángeles Pérez-Aisa, Juan Ortuño, Ines Modolell, Pedro Almela, Antonietta Gerarda Gravina, Nuria Fernández, Marco Martorano, Adrian G. McNicholl, Alfredo J. Lucendo, Jose Luis Domínguez, Teresa Angueira, Elisa Martin-Noguerol, Enrique Medina, Javier Molina-Infante, Javier P. Gisbert, Juan Enrique Domínguez-Muñoz, Manuel Rodríguez-Tellez, Miguel Fernández-Bermejo, Alessandro Federico, Alicia C Marin, Gisbert, Jp, Romano, Marco, Molina Infante, J, Lucendo, Aj, Medina, E, Modolell, I, Rodríguez Tellez, M, Gomez, B, Barrio, J, Perona, M, Ortuño, J, Ariño, I, Domínguez Muñoz, Je, Perez Aisa, Á, Bermejo, F, Domínguez, Jl, Almela, P, Gomez Camarero, J, Millastre, J, Martin Noguerol, E, Gravina, Ag, Martorano, M, Miranda, A, Federico, Alessandro, Fernandez Bermejo, M, Angueira, T, Ferrer Barcelo, L, Fernández, N, Marín, Ac, and Mcnicholl, Ag
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.drug_class ,Moxifloxacin ,Failure ,Proton-pump inhibitor ,Levofloxacin ,Quinolones ,Gastroenterology ,Esomeprazole ,Helicobacter Infections ,Cohort Studies ,Internal medicine ,medicine ,Humans ,Urea ,Prospective Studies ,Treatment Failure ,Adverse effect ,Eradication ,Hepatology ,Helicobacter pylori ,business.industry ,Amoxicillin ,Proton Pump Inhibitors ,Middle Aged ,Surgery ,Anti-Bacterial Agents ,Regimen ,Treatment Outcome ,Tolerability ,Breath Tests ,Rescue ,Concomitant ,Retreatment ,Drug Therapy, Combination ,Female ,Therapy ,business ,medicine.drug ,Fluoroquinolones - Abstract
Background: Aim was to evaluate the efficacy and tolerability of a moxifloxacin-containing second-line triple regimen in patients whose previous Helicobacter pylori eradication treatment failed. Methods: Prospective multicentre study including patients in whom a triple therapy or a non-bismuth-quadruple- therapy failed. Moxifloxacin (400 mg qd), amoxicillin (1 g bid), and esomeprazole (40 mg bid) were prescribed for 14 days. Eradication was confirmed by C-13-urea-breath-test. Compliance was determined through questioning and recovery of empty medication envelopes. Results: 250 patients were consecutively included (mean age 48 +/- 15 years, 11% with ulcer). Previous (failed) therapy included: standard triple (n = 179), sequential (n = 27), and concomitant (n = 44); 97% of patients took all medications, 4 were lost to follow-up. Intention-to-treat and per-protocol eradication rates were 82.4% (95% CI, 77-87%) and 85.7% (95% CI, 81-90%). Cure rates were similar independently of diagnosis (ulcer, 77%; dyspepsia, 82%) and previous treatment (standard triple, 83%; sequential, 89%; concomitant, 77%). At multivariate analysis, only age was associated with eradication (OR = 0.957; 95% CI, 0.933-0.981). Adverse events were reported in 25.2% of patients: diarrhoea (9.6%), abdominal pain (9.6%), and nausea (9.2%). Conclusion: 14-day moxifloxacin-containing triple therapy is an effective and safe second-line strategy in patients whose previous standard triple therapy or non-bismuth quadruple (sequential or concomitant) therapy has failed, providing a simple alternative to bismuth quadruple regimen. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
- Published
- 2014
25. Combined 17a-hydroxylase/17-20-lyase deficiency caused by Phe93Cys mutation in the CYP17 gene
- Author
-
Alfredo Di Cerbo, Anna Biason-Lauber, Maria Savino, Anna Di Giorgio, Maria Rosaria Piemontese, Anna Savoia, Marco Perona, DI CERBO, A, BIASON LAUBER, A, Savino, M, Piemontese, Mr, DI GIORGIO, A, Perona, M, and Savoia, Anna
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Molecular Sequence Data ,Consanguinity ,Human leukocyte antigen ,Biology ,medicine.disease_cause ,Biochemistry ,Dexamethasone ,Endocrinology ,Metabolic Diseases ,Internal medicine ,medicine ,Missense mutation ,Humans ,Congenital adrenal hyperplasia ,Glucocorticoids ,Conserved Sequence ,Genetics ,Mutation ,Adrenal Hyperplasia, Congenital ,Base Sequence ,Sexual Differentiation Disorder ,Biochemistry (medical) ,Haplotype ,Steroid 17-alpha-Hydroxylase ,Sexual Infantilism ,Middle Aged ,medicine.disease ,Hormones ,Pedigree ,Amino Acid Substitution ,Female ,Microsatellite Repeats - Abstract
Seventeen alpha-hydroxylase/17,20-lyase deficiency is a rare, autosomal recessive form of congenital adrenal hyperplasia not linked to human leukocyte antigen and characterized by the coexistence of hypertension caused by the hyperproduction of mineralocorticoid precursors and sexual abnormalities, such as male pseudohermaphroditism and sexual infantilism in female, due to impaired production of sex hormones. Both 17alpha-hydroxylase and 17,20-lyase reactions are catalyzed by a single polypeptide, cytochrome P450c17 (CYP17), which is encoded by the CYP17 gene located on chromosome 10q24-q25. Mutations in the CYP17 gene have been recognized to cause the 17alpha-hydroxylase/17,20-lyase deficiency syndrome. Here, we describe two phenotypically and hormonally affected Italian patients with 17alpha-hydroxylase/17,20-lyase deficiency. The family history revealed consanguinity of the parents. Linkage and haplotype analyses using microsatellites on chromosome 10q24-q25 demonstrated that the two affected individuals were homozygous at these loci. The mutation screening of the CYP17 gene identified a new Phe93Cys missense mutation in exon 1. The amino acid substitution is located in a highly conserved region of the protein and is not a polymorphism because it is not present in one hundred normal alleles. In vitro functional studies showed that the Phe93Cys mutated CYP17 retains only 10% of both 17alphahydroxylase and 17,20-lyase activities, according to the severe phenotype. Our results shed more light on the structure-function relationship of the CYP17 protein indicating that Phe 93 is crucial for both enzymatic activities.
- Published
- 2002
26. Symptomology, Outcomes and Risk Factors of Acute Coronary Syndrome Presentations without Cardiac Chest Pain: A Scoping Review.
- Author
-
Perona M, Cooklin A, Thorpe C, O'Meara P, and Rahman MA
- Abstract
For patients experiencing acute coronary syndrome, early symptom recognition is paramount; this is challenging without chest pain presentation. The aims of this scoping review were to collate definitions, proportions, symptoms, risk factors and outcomes for presentations without cardiac chest pain. Full-text peer reviewed articles covering acute coronary syndrome symptoms without cardiac chest pain were included. MEDLINE, CINAHL, Scopus and Embase were systematically searched from 2000 to April 2023 with adult and English limiters; 41 articles were selected from 2,954. Dyspnoea was the most reported (n=39) and most prevalent symptom (11.6-72%). Neurological symptoms, fatigue/weakness, nausea/ vomiting, atypical chest pain and diaphoresis were also common. Advancing age appeared independently associated with presentations without cardiac chest pain; however, findings were mixed regarding other risk factors (sex and diabetes). Patients without cardiac chest pain had worse outcomes: increased mortality, morbidity, greater prehospital and intervention delays and suboptimal use of guideline driven care. There is a need for structured data collection, analysis and interpretation., Competing Interests: Disclosure: AC has received a future fellowship grant from the Australian Research Council; PO has received consulting fees from The Paramedic Foundation and the Australian Health Professional Regulatory; is on the boards of The Paramedic Network, the American Paramedic Association and the Australasian College of Paramedicine Community Paramedic Working Party; and is director of the Global Paramedic Higher Education Council. All other authors have no conflicts of interest to declare. Authors’ contributions: Conceptualisation: MP and MAR; data curation: MP; formal analysis: MP, AC and MAR; funding acquisition: not applicable; investigation: MP and CT; methodology: MP and MAR; project administration: MP; resources: MP; software: not applicable; supervision: AC and MAR; validation: MP, AC and MAR; visualisation: MP; writing – original draft preparation: MP; writing – review & editing: MP, AC, CT, PO and MAR., (Copyright © The Author(s), 2024. Published by Radcliffe Group Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
27. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
- Author
-
Pabón-Carrasco M, Keco-Huerga A, Castro-Fernández M, Saracino IM, Fiorini G, Vaira D, Pérez-Aísa Á, Tepes B, Jonaitis L, Voynovan I, Lucendo AJ, Lanas Á, Martínez-Domínguez SJ, Almajano EA, Rodrigo L, Vologzanina L, Brglez Jurecic N, Denkovski M, Bujanda L, Abdulkhakov RA, Huguet JM, Fernández-Salazar L, Alcaide N, Velayos B, Silkanovna Sarsenbaeva A, Zaytsev O, Ilchishina T, Barrio J, Bakulin I, Perona M, Alekseenko S, Romano M, Gravina AG, Núñez Ó, Gómez Rodríguez BJ, Ledro-Cano D, Pellicano R, Bogomolov P, Domínguez-Cajal M, Almela P, Gomez-Camarero J, Bordin DS, Gasbarrini A, Kupčinskas J, Cano-Català A, Moreira L, Nyssen OP, Mégraud F, O'Morain C, and Gisbert JP
- Subjects
- Adult, Humans, Proton Pump Inhibitors therapeutic use, Metronidazole, Clarithromycin therapeutic use, Levofloxacin therapeutic use, Bismuth, Prospective Studies, Drug Therapy, Combination, Anti-Bacterial Agents therapeutic use, Amoxicillin therapeutic use, Tetracycline, Registries, Helicobacter pylori, Helicobacter Infections drug therapy
- Abstract
Background: Management of Helicobacter pylori (H. pylori) infection requires co-treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication., Aim: To evaluate the role of dosage of PPIs and the duration of therapy in the effectiveness of H. pylori eradication treatments based on the 'European Registry on Helicobacter pylori management' (Hp-EuReg)., Methods: Hp-EuReg is a multicentre, prospective, non-interventionist, international registry on the routine clinical practice of H. pylori management by European gastroenterologists. All infected adult patients were systematically registered from 2013 to 2022., Results: Overall, 36,579 patients from five countries with more than 1000 patients were analysed. Optimal (≥90%) first-line-modified intention-to-treat effectiveness was achieved with the following treatments: (1) 14-day therapies with clarithromycin-amoxicillin-bismuth and metronidazole-tetracycline-bismuth, both independently of the PPI dose prescribed; (2) All 10-day (except 10-day standard triple therapy) and 14-day therapies with high-dose PPIs; and (3) 10-day quadruple therapies with clarithromycin-amoxicillin-bismuth, metronidazole-tetracycline-bismuth, and clarithromycin-amoxicillin-metronidazole (sequential), all with standard-dose PPIs. In first-line treatment, optimal effectiveness was obtained with high-dose PPIs in all 14-day treatments, in 10- and 14-day bismuth quadruple therapies and in 10-day sequential with standard-dose PPIs. Optimal second-line effectiveness was achieved with (1) metronidazole-tetracycline-bismuth quadruple therapy for 14- and 10 days with standard and high-dose PPIs, respectively; and (2) levofloxacin-amoxicillin triple therapy for 14 days with high-dose PPIs. None of the 7-day therapies in both treatment lines achieved optimal effectiveness., Conclusions: We recommend, in first-line treatment, the use of high-dose PPIs in 14-day triple therapy and in 10-or 14-day quadruple concomitant therapy in first-line treatment, while standard-dose PPIs would be sufficient in 10-day bismuth quadruple therapies. On the other hand, in second-line treatment, high-dose PPIs would be more beneficial in 14-day triple therapy with levofloxacin and amoxicillin or in 10-day bismuth quadruple therapy either as a three-in-one single capsule or in the traditional scheme., (© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
28. Selenium bioavailability modulates the sensitivity of thyroid cells to iodide excess.
- Author
-
Oglio R, Rodriguez C, Salvarredi L, Rossich L, Perona M, Dagrosa A, Juvenal G, and Thomasz L
- Subjects
- Rats, Animals, Iodides metabolism, Transforming Growth Factor beta1 metabolism, Proto-Oncogene Proteins c-akt metabolism, Reactive Oxygen Species metabolism, Biological Availability, Phosphatidylinositol 3-Kinases metabolism, NF-E2-Related Factor 2 genetics, NF-E2-Related Factor 2 metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Thyroid Gland metabolism, Selenium pharmacology, Selenium metabolism
- Abstract
Introduction: Iodide is an essential micronutrient for the synthesis of thyroid hormones and its imbalance is involved in the origin of different thyroid pathological processes. Selenium (Se) is another essential trace element that contributes to thyroid preservation through the control of the redox homeostasis. Different studies have demonstrated that sodium-iodide-symporter (NIS) is downregulated in the presence of iodide excess and Se supplementation reverses this effect. We also demonstrated that NOX4-derived ROS are involved in NIS repression induced by iodide excess. The aim of this study was to investigate how Se bioavailability is decisive in the sensitivity to iodide excess on a differentiated rat thyroid cell line (FRTL-5)., Results: We demonstrated that siRNA-mediated silencing of Nox4 suppressed AKT phosphorylation induced by iodide excess. Iodide increases TGF-β1 mRNA expression, AKT phosphorylation, ROS levels and decreases GPX1 and TXRND1 mRNAs expression while Se reversed these effects. Furthermore, iodide induced Nrf2 transcriptional activity only in Se-supplemented cultures, suggesting that Se positively influences Nrf2 activation and selenoenzyme response in FRTL-5. Se, also inhibited NF-κB phosphorylation induced by iodide excess. In addition, we found that iodide excess decreased total phosphatase activity and PTP1B and PTEN mRNA expression. Se supply restored only PTEN mRNA expression. Finally, we studied the 2-α-iodohexadecanal (2-IHD) effects since it has been proposed as intermediary of iodide action on thyroid autoregulation. 2-IHD stimulated PI3K/AKT activity and reduced NIS expression by a ROS-independent mechanism. Also, we found that 2-IHD increased TGF-β1 mRNA and TGF-β inhibitor (SB431542) reverses the 2-IHD inhibitory effect on NIS mRNA expression, suggesting that TGF-β1 signaling pathway could be involved. Although Se reduced 2-IHD-induced TGFB1 levels, it could not reverse its inhibitory effect on NIS expression., Conclusion: Our study suggests that Se bioavailability may improve the expression of antioxidant genes through the activation of Nrf2, interfere in PI3K/AKT signaling and NIS expression by redox modulation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Safety in training for ultrasound guided internal jugular vein CVC placement: a propensity score analysis.
- Author
-
De Cassai A, Geraldini F, Pasin L, Boscolo A, Zarantonello F, Tocco M, Pretto C, Perona M, Carron M, and Navalesi P
- Subjects
- Aged, Cohort Studies, Female, Humans, Internship and Residency, Italy, Male, Propensity Score, Retrospective Studies, Catheterization, Central Venous methods, Clinical Competence statistics & numerical data, Jugular Veins diagnostic imaging, Patient Safety, Ultrasonography, Interventional methods
- Abstract
Background: Central venous catheter (CVC) placement is a routine procedure but is potentially associated with severe complications. Relatively small studies investigated if the use of ultrasound is effective in bridging the skill gap between proficient and not proficient operators, while patient safety during training remains a controversial topic. The first aim of this study was to evaluate if resident proficiency affects the failure rate in CVC positioning under ultrasound guidance. In addition, it aimed to investigate the different rate of complications between proficient and non proficient residents., Methods: We conducted a cohort study including CVC placed by residents at the University Hospital of Padova, from November 1, 2012 to July 9, 2020 comparing proficient and non proficient residents. To avoid bias the two cohorts were matched using propensity score., Results: A total of 356 residents positioned 2310 CVC during the 8 year study period. Among them, two groups of 1060 CVCs each were matched with a propensity score analysis. There was no difference in the failure rate among the groups (2.8 vs 2.7%, p-value 0.895). Moreover, cohorts had the same rate of hematomas, catheter tip malposition, arterial puncture and pneumothorax. No cases of hemothorax were reported., Conclusions: We found the same rate of success and incidence of adverse complications among cohorts, meaning that the process of skill acquisition is safe as long as appropriate training and direct supervision by a senior consultant are available., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
30. Non-acid reflux and sleep apnea: the importance of drug induced sleep endoscopy.
- Author
-
O'Connor-Reina C, Garcia JMI, Baptista P, Garcia-Iriarte MT, Alba CC, Perona M, Borrmann PF, Alcala LR, and Plaza G
- Subjects
- Gastroesophageal Reflux complications, Gastroesophageal Reflux drug therapy, Humans, Male, Middle Aged, Polysomnography, Sleep Apnea Syndromes physiopathology, Esophagoscopy methods, Gastroesophageal Reflux diagnosis, Proton Pump Inhibitors therapeutic use, Sleep, Sleep Apnea Syndromes complications
- Abstract
Background: We present the first case of a patient with obstructive sleep apnea syndrome (OSA), where drug induced sleep endoscopy was helpful to suspect a non-acid reflux disease and showed an improvement in a swollen epiglottis after treatment. Patient ameliorated significantly his disease only with medical therapy., Case Presentation: A 54-year-old man without significant anatomical findings with obstructive sleep apnea syndrome and non-acid gastroesophageal reflux disease (GERD) disease whose Apnea- hypopnea index (AHI) was significantly reduced with the intake of 500 mg of sodium alginate twice a day for 6 months. Conventional digestive tests such as esophagoscopy and simple- and double-channel 24-h pH-metry suggested mild GERD. Conventional proton-pump inhibitor treatment with pantoprazole (40 mg daily) was started without any improvement in his sleep. Multichannel intraluminal 24-h impedanciometry indicated the presence of severe pathological GER of gaseous origin. The patient's AHI decreased from 25.3 at baseline to 8 after treatment with sodium alginate. A drug-induced sleep endoscopy study showed the changes before and after this treatment and was helpful for the diagnosis., Conclusions: Thus, medical treatment can be a therapeutic option in some patients with OSA. Multichannel 24-h impedanciometry should be performed when nonacid GERD is suspected.
- Published
- 2021
- Full Text
- View/download PDF
31. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
- Author
-
Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, and Gisbert JP
- Subjects
- Adolescent, Adult, Anti-Bacterial Agents adverse effects, Bismuth adverse effects, Capsules, Drug Combinations, Drug Resistance, Bacterial, Europe, Female, Humans, Intention to Treat Analysis, Male, Medication Adherence, Metronidazole administration & dosage, Metronidazole adverse effects, Middle Aged, Proton Pump Inhibitors adverse effects, Registries, Tetracycline administration & dosage, Tetracycline adverse effects, Young Adult, Anti-Bacterial Agents administration & dosage, Bismuth administration & dosage, Gastrointestinal Diseases drug therapy, Gastrointestinal Diseases microbiology, Helicobacter Infections drug therapy, Helicobacter pylori, Proton Pump Inhibitors administration & dosage
- Abstract
Background: There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation., Objective: To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy., Methods: Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pylori infection, where patients were registered at the Asociación Española de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line., Results: Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e., three capsules every 6 h for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n = 1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n = 375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n = 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases., Conclusions: Single-capsule bismuth quadruple therapy achieved H. pylori eradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourable safety profile., (© 2020 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.)
- Published
- 2021
- Full Text
- View/download PDF
32. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain.
- Author
-
Caldas M, Pérez-Aisa Á, Castro-Fernández M, Bujanda L, Lucendo AJ, Rodrigo L, Huguet JM, Pérez-Lasala J, Molina-Infante J, Barrio J, Fernández-Salazar L, Lanas Á, Perona M, Domínguez-Cajal M, Ortuño J, Gómez-Rodríguez BJ, Almela P, Botargués JM, Núñez Ó, Modolell I, Gómez J, Ruiz-Zorrilla R, De la Coba C, Huerta A, Iyo E, Pozzati L, Antón R, Barenys M, Angueira T, Fernández-Bermejo M, Campillo A, Alcedo J, Pajares-Villaroya R, Mego M, Bermejo F, Dominguez-Jiménez JL, Titó L, Fernández N, Pabón-Carrasco M, Cosme Á, Mata-Romero P, Alcaide N, Ariño I, Di Maira T, Garre A, Puig I, Nyssen OP, Megraud F, O'Morain C, and Gisbert JP
- Abstract
The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. "Optimized" H. pylori therapies achieve over 90% success in Spain.
- Published
- 2020
- Full Text
- View/download PDF
33. Self-Detection of the LH Surge in Urine After GnRH Agonist Trigger in IVF-How to Minimize Failure to Retrieve Oocytes.
- Author
-
Cozzolino M, Matey S, Alvarez A, Toribio M, López V, Perona M, Henzenn E, Piró M, Humaidan P, and Garcia-Velasco JA
- Subjects
- Adolescent, Adult, Female, Fertilization in Vitro methods, Follow-Up Studies, Humans, Infertility, Female pathology, Infertility, Female urine, Oocytes physiology, Prospective Studies, Young Adult, Fertility Agents, Female pharmacology, Gonadotropin-Releasing Hormone agonists, Infertility, Female therapy, Luteinizing Hormone urine, Oocytes drug effects, Oogenesis, Ovulation Induction methods
- Abstract
Research question: Urine LH testing may be useful to confirm an LH surge after the GnRH agonist (GnRHa) trigger prior to oocyte retrieval in IVF. Design: A prospective cohort study, including oocyte donors undergoing ovarian stimulation, treated with a GnRHa trigger for final oocyte maturation. Urine LH testing was performed at home, 12 h after the GnRHa trigger. In the case of a negative result, serum LH and progesterone measurements were done that same day. Donors with no serum LH peak after trigger were re-scheduled using a dual trigger, with GnRHa and hCG. Results: Three hundred and fifty nine oocyte donors were included in the analysis. Three hundred and fifty six donors had positive urine LH tests, followed by oocyte retrieval. In one case, the LH test was positive, however, no oocytes were retrieved (false positive 1/356). Three LH tests were negative in urine: in one of these three cases, LH was tested again in blood, confirming an LH rise, consistent with an optimal response to the GnRHa trigger; in the other two cases, serum LH was <15 mUI/mL, after which the oocyte retrieval was re-scheduled for 36 h after an being re-triggered, resulting in the retrieval of 19 and 22 MII oocytes, respectively. Considering the cost analysis, it would be a significantly cost-saving strategy, as blood testing would have costed 14,840€ vs. only 185.5€ in urine LH kits. Conclusions: Urinary testing of the LH surge after GnRHa trigger is easy, safe, reliable, and convenient. In addition, LH urine testing allows identifying donors and patients who could benefit from a rescue hCG trigger after an unsuccessful GnRHa trigger., (Copyright © 2020 Cozzolino, Matey, Alvarez, Toribio, López, Perona, Henzenn, Piró, Humaidan and Garcia-Velasco.)
- Published
- 2020
- Full Text
- View/download PDF
34. Transcriptomic and genetic analyses reveal potential causal drivers for intractable partial epilepsy.
- Author
-
Guelfi S, Botia JA, Thom M, Ramasamy A, Perona M, Stanyer L, Martinian L, Trabzuni D, Smith C, Walker R, Ryten M, Reimers M, Weale ME, Hardy J, and Matarin M
- Subjects
- Adolescent, Adult, Epilepsies, Partial pathology, Epilepsy, Temporal Lobe metabolism, Female, Genetic Testing, Genome-Wide Association Study, Hippocampus metabolism, Humans, Male, Middle Aged, Sclerosis genetics, Sclerosis pathology, Drug Resistant Epilepsy genetics, Epilepsies, Partial genetics, Gene Expression Profiling, Transcriptome genetics
- Abstract
Mesial temporal lobe epilepsy with hippocampal sclerosis represents the most common epilepsy syndrome in adult patients with medically intractable partial epilepsy. Mesial temporal lobe epilepsy is usually regarded as a polygenic and complex disorder, still poorly understood but probably caused and perpetuated by dysregulation of numerous biological networks and cellular functions. The study of gene expression changes by single nucleotide polymorphisms in regulatory elements (expression quantitative trait loci, eQTLs) has been shown to be a powerful complementary approach to the detection and understanding of risk loci by genome-wide association studies. We performed a whole (gene and exon-level) transcriptome analysis on cortical tissue samples (Brodmann areas 20 and 21) from 86 patients with mesial temporal lobe epilepsy with hippocampal sclerosis and 75 neurologically healthy controls. Genome-wide genotyping data from the same individuals (patients and controls) were analysed and paired with the transcriptome data. We report potential epilepsy-risk eQTLs, some of which are specific to tissue from patients with mesial temporal lobe epilepsy with hippocampal sclerosis. We also found large transcriptional and splicing deregulation in mesial temporal lobe epilepsy with hippocampal sclerosis tissue as well as gene networks involving neuronal and glial mechanisms that provide new insights into the cause and maintenance of the seizures. These data (available via the 'Seizubraineac' web-tool resource, www.seizubraineac.org) will facilitate the identification of new therapeutic targets and biomarkers as well as genetic risk variants that could influence epilepsy and pharmacoresistance., (© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
35. The impact of brain-derived neurotrophic factor Val66Met polymorphism on cognition and functional brain networks in patients with intractable partial epilepsy.
- Author
-
Sidhu MK, Thompson PJ, Wandschneider B, Foulkes A, de Tisi J, Stretton J, Perona M, Thom M, Bonelli SB, Burdett J, Williams E, Duncan JS, and Matarin M
- Subjects
- Adult, Drug Resistant Epilepsy physiopathology, England epidemiology, Epilepsies, Partial physiopathology, Epilepsy, Temporal Lobe physiopathology, Female, Gene Frequency, Genotype, Hippocampus physiopathology, Humans, Magnetic Resonance Imaging, Male, Memory, Neuropsychological Tests, Neurosurgical Procedures, Psychomotor Performance, Brain-Derived Neurotrophic Factor genetics, Cognitive Dysfunction etiology, Cognitive Dysfunction psychology, Drug Resistant Epilepsy genetics, Drug Resistant Epilepsy psychology, Epilepsies, Partial genetics, Epilepsies, Partial psychology, Epilepsy, Temporal Lobe genetics, Epilepsy, Temporal Lobe psychology, Nerve Net physiopathology, Polymorphism, Genetic genetics
- Abstract
Introduction: Medial temporal lobe epilepsy (mTLE) is the most common refractory focal epilepsy in adults. Around 30%-40% of patients have prominent memory impairment and experience significant postoperative memory and language decline after surgical treatment. BDNF Val66Met polymorphism has also been associated with cognition and variability in structural and functional hippocampal indices in healthy controls and some patient groups., Aims: We examined whether BDNF Val66Met variation was associated with cognitive impairment in mTLE., Methods: In this study, we investigated the association of Val66Met polymorphism with cognitive performance (n = 276), postoperative cognitive change (n = 126) and fMRI activation patterns during memory encoding and language paradigms in 2 groups of patients with mTLE (n = 37 and 34)., Results: mTLE patients carrying the Met allele performed more poorly on memory tasks and showed reduced medial temporal lobe activation and reduced task-related deactivations within the default mode networks in both the fMRI memory and language tasks than Val/Val patients., Conclusions: Although cognitive impairment in epilepsy is the result of a complex interaction of factors, our results suggest a role of genetic factors on cognitive impairment in mTLE., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
36. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology.
- Author
-
Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, Nahaboo Solim MA, Moens TG, Paublete RM, Ali SS, Perona M, Desai R, Smith KJ, Latcham J, Fulleylove M, Richardson JC, Hardy J, and Edwards FA
- Subjects
- Animals, Brain metabolism, Dementia metabolism, Humans, Mice, Mice, Transgenic, Plaque, Amyloid metabolism, tau Proteins metabolism, Gene Expression Regulation, Genome-Wide Association Study, Plaque, Amyloid genetics, tau Proteins genetics
- Abstract
We provide microarray data comparing genome-wide differential expression and pathology throughout life in four lines of "amyloid" transgenic mice (mutant human APP, PSEN1, or APP/PSEN1) and "TAU" transgenic mice (mutant human MAPT gene). Microarray data were validated by qPCR and by comparison to human studies, including genome-wide association study (GWAS) hits. Immune gene expression correlated tightly with plaques whereas synaptic genes correlated negatively with neurofibrillary tangles. Network analysis of immune gene modules revealed six hub genes in hippocampus of amyloid mice, four in common with cortex. The hippocampal network in TAU mice was similar except that Trem2 had hub status only in amyloid mice. The cortical network of TAU mice was entirely different with more hub genes and few in common with the other networks, suggesting reasons for specificity of cortical dysfunction in FTDP17. This Resource opens up many areas for investigation. All data are available and searchable at http://www.mouseac.org., (Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
37. [Coordination between levels of care: what are the priorities for the healthcare professionals?].
- Author
-
Allepuz A, Gallardo C, and Perona M
- Subjects
- Humans, Delivery of Health Care organization & administration, Health Personnel, Health Priorities
- Published
- 2012
- Full Text
- View/download PDF
38. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study.
- Author
-
Mearin F, Pérez-Oliveras M, Perelló A, Vinyet J, Ibañez A, Coderch J, and Perona M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Disease Outbreaks, Dyspepsia epidemiology, Female, Follow-Up Studies, Humans, Irritable Bowel Syndrome epidemiology, Male, Middle Aged, Prospective Studies, Risk Factors, Salmonella Infections epidemiology, Surveys and Questionnaires, Dyspepsia microbiology, Irritable Bowel Syndrome microbiology, Salmonella Infections complications, Salmonella enteritidis
- Abstract
Background & Aims: It has been reported that some patients develop functional digestive disorders, particularly irritable bowel syndrome (IBS), after acute gastroenteritis (AGE). However, the presence of dyspepsia has not been specifically addressed. We prospectively evaluated development of dyspepsia and IBS during a 1-year follow-up in a cohort of adult patients affected by a Salmonella enteritidis AGE outbreak., Methods: Questionnaires were sent to 1878 potential participants at baseline and 3, 6, and 12 months; 677 had experienced a Salmonella enteritidis AGE on June 23, 2002, and 1201 had not (randomly selected controls, matched for village of residence, age, and sex). At 12 months, 271 patients and 335 controls returned the questionnaires. Data permitted the establishment of dyspepsia and IBS diagnosis by Rome II criteria., Results: Before the AGE outbreak, the prevalence of dyspepsia was similar in cases and controls (2.5% vs 3.8%); the prevalence of IBS was also similar (2.9% vs 2.3%). At 3, 6, and 12 months, the prevalence of both dyspepsia and IBS had increased significantly in exposed compared with unexposed subjects. Overlap between dyspepsia and IBS was frequent. At 1 year, the relative risk for development of dyspepsia was 5.2 (95% confidence interval, 2.7-9.8) and for IBS was 7.8 (95% confidence interval, 3.1-19.7). Prolonged abdominal pain and vomiting during AGE were positive predictors of dyspepsia. No predictive factors for IBS were found., Conclusions: Salmonella gastroenteritis is a significant risk factor not only for IBS but also for dyspepsia; at 1 year of follow-up, 1 in 7 and 1 in 10 subjects developed dyspepsia or IBS, respectively.
- Published
- 2005
- Full Text
- View/download PDF
39. Prevalence of functional gastrointestinal disorders in women who report domestic violence to the police.
- Author
-
Perona M, Benasayag R, Perelló A, Santos J, Zárate N, Zárate P, and Mearin F
- Subjects
- Adult, Aged, Dyspepsia psychology, Female, Humans, Interviews as Topic, Irritable Bowel Syndrome psychology, Middle Aged, Patient Acceptance of Health Care statistics & numerical data, Police, Prevalence, Retrospective Studies, Sex Offenses psychology, Spain epidemiology, Stress, Psychological epidemiology, Surveys and Questionnaires, Domestic Violence psychology, Dyspepsia epidemiology, Irritable Bowel Syndrome epidemiology
- Abstract
Background & Aims: Retrospective studies found an association between past sexual, physical, or psychological abuse and functional gastrointestinal disorders (FGIDs). However, there are no studies evaluating such an association concurrently with the ongoing abuse. Our aim was to investigate the prevalence of the main FGIDs, functional dyspepsia and irritable bowel syndrome, in 70 women reporting a situation of domestic violence to the police and to evaluate the level of psychological distress and its relationship with the presence of FGID., Methods: Through an interview between a social worker and the woman reporting abuse, digestive symptoms, psychological status, and type of abuse were recorded. These data were matched against police records. Functional dyspepsia and irritable bowel syndrome were diagnosed according to Rome II criteria., Results: Seventy-one percent of the women had an FGID: 67% functional dyspepsia, 47% irritable bowel syndrome, and 43% both. In two thirds of the cases, FGID onset occurred simultaneously with or soon after abuse onset. Only 34% of the women had sought medical attention for FGID symptoms. No differences were found between women with or without FGID regarding age and type or duration of abuse; psychological distress tended to be more severe in the group of women with FGIDs., Conclusions: Most women who suffer domestic violence (reported to the police) have functional dyspepsia and/or irritable bowel syndrome and also have elevated psychological distress. This has important implications, not only for comprehensive health care of women in a situation of abuse, but also for medical treatment of women with FGIDs.
- Published
- 2005
- Full Text
- View/download PDF
40. Combined 17alpha-Hydroxylase/17,20-lyase deficiency caused by Phe93Cys mutation in the CYP17 gene.
- Author
-
Di Cerbo A, Biason-Lauber A, Savino M, Piemontese MR, Di Giorgio A, Perona M, and Savoia A
- Subjects
- Adolescent, Adult, Amino Acid Substitution, Base Sequence genetics, Conserved Sequence, Female, Hormones blood, Hormones urine, Humans, Male, Metabolic Diseases drug therapy, Metabolic Diseases genetics, Microsatellite Repeats, Middle Aged, Molecular Sequence Data, Pedigree, Adrenal Hyperplasia, Congenital, Dexamethasone therapeutic use, Glucocorticoids therapeutic use, Mutation physiology, Steroid 17-alpha-Hydroxylase genetics
- Abstract
Seventeen alpha-hydroxylase/17,20-lyase deficiency is a rare, autosomal recessive form of congenital adrenal hyperplasia not linked to human leukocyte antigen and characterized by the coexistence of hypertension caused by the hyperproduction of mineralocorticoid precursors and sexual abnormalities, such as male pseudohermaphroditism and sexual infantilism in female, due to impaired production of sex hormones. Both 17alpha-hydroxylase and 17,20-lyase reactions are catalyzed by a single polypeptide, cytochrome P450c17 (CYP17), which is encoded by the CYP17 gene located on chromosome 10q24-q25. Mutations in the CYP17 gene have been recognized to cause the 17alpha-hydroxylase/17,20-lyase deficiency syndrome. Here, we describe two phenotypically and hormonally affected Italian patients with 17alpha-hydroxylase/17,20-lyase deficiency. The family history revealed consanguinity of the parents. Linkage and haplotype analyses using microsatellites on chromosome 10q24-q25 demonstrated that the two affected individuals were homozygous at these loci. The mutation screening of the CYP17 gene identified a new Phe93Cys missense mutation in exon 1. The amino acid substitution is located in a highly conserved region of the protein and is not a polymorphism because it is not present in one hundred normal alleles. In vitro functional studies showed that the Phe93Cys mutated CYP17 retains only 10% of both 17alphahydroxylase and 17,20-lyase activities, according to the severe phenotype. Our results shed more light on the structure-function relationship of the CYP17 protein indicating that Phe 93 is crucial for both enzymatic activities.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.